Is selinesol suitable for treating lymphoma?

Selinexor (Selinexor) is a selective nuclear export inhibitor (SINE drugs). By blocking the function of nuclear export protein XPO1, it inhibits the abnormal localization and degradation of a variety of cancer-related proteins and restores the normal function of tumor suppressors. This mechanism enables selinesol to exhibit broad anti-cancer potential in a variety of hematological malignancies, especially in the treatment of refractory or relapsed lymphoma.

Currently, selinesol is approved for the treatment of certain types of lymphoma, specifically relapsed or refractory diffuse large B cell lymphoma (DLBCL). These patients are often no longer sensitive to standard treatments and have limited treatment options, and selinesol provides a new treatment avenue for these patients. Studies have shown that the objective response rate of selinesol monotherapy for DLBCL patients is above 20%, and some patients can achieve longer-term disease control, showing certain clinical value.

In addition, selinesol is also being studied for use in combination with other drugs to treat different types of lymphoma, including mantle cell lymphoma, peripheral T cell lymphoma, etc. Combination regimens are designed to enhance efficacy and delay the development of drug resistance. Although the effectiveness of single agents is limited, combination immunochemotherapy or targeted therapy is gradually expanding its indications and being evaluated in multiple clinical trials.

Overall, selinesol does appear to be useful in treating certain types of lymphoma, particularly in relapsed and refractory patients who have failed multiple therapies. During use, you need to pay attention to the adverse reactions of the drug, such as loss of appetite, nausea, fatigue, cytopenia, etc. It is recommended to use the drug under the guidance of a professional doctor, and closely monitor the patient's tolerance and treatment response. As research deepens, the role of selinesol in the treatment of lymphoma is expected to be further expanded.

Reference materials:https://www.selincro.com/